Literature DB >> 27247218

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Lowell E Schnipper1, Nancy E Davidson2, Dana S Wollins2, Douglas W Blayney2, Adam P Dicker2, Patricia A Ganz2, J Russell Hoverman2, Robert Langdon2, Gary H Lyman2, Neal J Meropol2, Therese Mulvey2, Lee Newcomer2, Jeffrey Peppercorn2, Blase Polite2, Derek Raghavan2, Gregory Rossi2, Leonard Saltz2, Deborah Schrag2, Thomas J Smith2, Peter P Yu2, Clifford A Hudis2, Julie M Vose2, Richard L Schilsky2.   

Abstract

Mesh:

Year:  2016        PMID: 27247218     DOI: 10.1200/JCO.2016.68.2518

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  129 in total

1.  Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost.

Authors:  Theresa A Hastert; Jaclyn M Kyko; Amanda R Reed; Felicity W K Harper; Jennifer L Beebe-Dimmer; Tara E Baird; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-06       Impact factor: 4.254

Review 2.  Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

Authors:  Meng Qiao; Tao Jiang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.

Authors:  Grace Lu-Yao; Nikita Nikita; Scott W Keith; Ginah Nightingale; Krupa Gandhi; Sarah E Hegarty; Timothy R Rebbeck; Andrew Chapman; Philip W Kantoff; Jennifer Cullen; Leonard Gomella; William Kevin Kelly
Journal:  Eur Urol       Date:  2019-08-13       Impact factor: 20.096

5.  Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Davendra P S Sohal; Erin B Kennedy; Alok Khorana; Mehmet S Copur; Christopher H Crane; Ignacio Garrido-Laguna; Smitha Krishnamurthi; Cassadie Moravek; Eileen M O'Reilly; Philip A Philip; Ramesh K Ramanathan; Joseph T Ruggiero; Manish A Shah; Susan Urba; Hope E Uronis; Michelle W Lau; Daniel Laheru
Journal:  J Clin Oncol       Date:  2018-05-23       Impact factor: 44.544

Review 6.  Mitigating the adverse health effects and costs associated with smoking after a cancer diagnosis.

Authors:  Graham W Warren
Journal:  Transl Lung Cancer Res       Date:  2019-05

7.  Another disappointing result, but how good is it?

Authors:  Yasushi Goto
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

8.  Defining Value: The Need for a Longer, Broader View.

Authors:  Tomas J Philipson; Sachin Kamal-Bahl; Anupam B Jena
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

9.  Approvals in 2016: questioning the clinical benefit of anticancer therapies.

Authors:  Christopher M Booth; Joseph C Del Paggio
Journal:  Nat Rev Clin Oncol       Date:  2017-02-20       Impact factor: 66.675

10.  Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.

Authors:  W W L Wong; M Zargar; S R Berry; Y J Ko; M Riesco-Martínez; K K W Chan
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.